- In May 2024, EUSA Pharma (a Recordati company) announced the expansion of its angiosarcoma-focused research program with new clinical trials evaluating the efficacy of tacrolimus-based targeted therapy in treating advanced hemangiosarcoma. This initiative aims to explore immune-modulating pathways and underscores the company’s commitment to developing effective solutions for rare and aggressive cancers. The trials are expected to provide critical data that could reshape treatment guidelines for late-stage angiosarcoma patients
- In April 2024, SpringWorks Therapeutics entered a collaborative agreement with several sarcoma research networks across North America and Europe to study the application of its gamma-secretase inhibitors in soft tissue sarcomas, including angiosarcoma. The partnership is focused on harnessing pathway-specific inhibition to disrupt tumor progression and highlights the growing role of precision medicine in rare oncology therapeutics
- In March 2024, Merck & Co., Inc. initiated a Phase II clinical trial assessing the use of Keytruda (pembrolizumab) in combination with anti-angiogenic agents for the treatment of recurrent angiosarcoma. The study reflects the rising interest in combining immunotherapy with anti-vascular therapies to improve treatment efficacy and patient outcomes in this aggressive tumor type
- In February 2024, the Sarcoma Alliance for Research through Collaboration (SARC) announced the launch of a global angiosarcoma patient registry, aimed at consolidating clinical data, treatment outcomes, and genetic information. This initiative is expected to accelerate research, inform therapeutic development, and improve clinical decision-making through real-world evidence
- In January 2024, Deciphera Pharmaceuticals presented promising preclinical data on a novel pan-kinase inhibitor, specifically targeting pathways involved in vascular tumor growth, including angiosarcoma. The findings were shared at the American Society of Clinical Oncology (ASCO) Rare Cancers Symposium and demonstrated strong potential in reducing tumor proliferation. This development aligns with the increasing demand for innovative therapies tailored to the complex biology of angiosarcoma
